Prevalence of BRAF, NRAS and c-KIT Mutations in Slovenian Patients with Advanced Melanoma
暂无分享,去创建一个
V. Zadnik | S. Novaković | J. Ocvirk | M. E. Moltara | M. Boc | M. Reberšek | Marina Bučić
[1] G. Ullenhag,et al. Discrepancy in BRAF status among patients with metastatic malignant melanoma: A meta-analysis. , 2017, European journal of cancer.
[2] V. Zadnik,et al. Cancer burden in slovenia with the time trends analysis , 2017, Radiology and oncology.
[3] J. Mosser,et al. Prognostic and predictive values of oncogenic BRAF, NRAS, c‐KIT and MITF in cutaneous and mucous melanoma , 2015, Journal of the European Academy of Dermatology and Venereology : JEADV.
[4] Soo-Nyung Kim,et al. Metaanalysis of BRAF mutations and clinicopathologic characteristics in primary melanoma. , 2015, Journal of the American Academy of Dermatology.
[5] A. Iafrate,et al. Impact of NRAS Mutations for Patients with Advanced Melanoma Treated with Immune Therapies , 2015, Cancer Immunology Research.
[6] K. Tsuta,et al. BRAF V600 mutations and pathological features in Japanese melanoma patients , 2014, Melanoma research.
[7] R. Scolyer,et al. Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma , 2014, British Journal of Cancer.
[8] O. Griffith,et al. COSMIC (Catalogue of Somatic Mutations in Cancer) , 2014 .
[9] Michael A. Davies,et al. Pathways and therapeutic targets in melanoma , 2014, Oncotarget.
[10] Dirk Schadendorf,et al. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. , 2014, The Lancet. Oncology.
[11] M. Mandalà,et al. Targeting BRAF in melanoma: biological and clinical challenges. , 2013, Critical reviews in oncology/hematology.
[12] J. Ferlay,et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. , 2013, European journal of cancer.
[13] C. Ng,et al. NRAS mutation status is an independent prognostic factor in metastatic melanoma , 2012, Cancer.
[14] A. Sivachenko,et al. A Landscape of Driver Mutations in Melanoma , 2012, Cell.
[15] G. Botti,et al. BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] Lauren E Haydu,et al. Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma , 2012, Clinical Cancer Research.
[17] C. Tzen,et al. Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma , 2011, Pigment cell & melanoma research.
[18] C. Antonescu,et al. KIT as a therapeutic target in metastatic melanoma. , 2011, JAMA.
[19] G. Mann,et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] R. Scolyer,et al. BRAF mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor, and the degree of solar elastosis at the primary tumor site , 2011, Pigment cell & melanoma research.
[21] J. Choi,et al. Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta‐analysis , 2011, The British journal of dermatology.
[22] A. Hauschild,et al. Melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[23] Shicai Wang,et al. COSMIC: the Catalogue Of Somatic Mutations In Cancer , 2018, Nucleic Acids Res..
[24] J. Lundeberg,et al. NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing , 2006, Melanoma research.
[25] D. Pinkel,et al. Somatic activation of KIT in distinct subtypes of melanoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] J. Fridlyand,et al. Distinct sets of genetic alterations in melanoma. , 2005, The New England journal of medicine.
[27] A. Hauschild,et al. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.